Results of a Questionnaire Survey on Off-label Use of Pirarubicin in the Treatment of Malignant Solid Tumors in Children

• Ikeda Hitoshi

  Department of Pediatric Surgery, Dokkyo Medical University Koshigaya Hospital

• Morikawa Yasuhide

  Department of Pediatric Surgery, International University of Health and Welfare

• Fukuzawa Masahiro

  Department of Pediatric Surgery, Osaka University Graduate School of Medicine

• Hiyama Eiso

  Department of Pediatric Surgery, Hiroshima University Graduate School of Biomedical Sciences

Bibliographic Information

Other Title

• ピラルビシン(THP)の小児固形がんにおける保険適応外使用に関するアンケート調査の結果
• ピラルビシン(THP)ノ ショウニ コケイ ガン ニ オケル ホケン テキオウ ガイ シヨウ ニ カンスル アンケート チョウサ ノ ケッカ

Abstract

Purpose: To clarify the number of hospitals which have adopted the off-label use of pirarubicin (THP) in the treatment of malignant solid tumors in children. Materials and Methods: A survey involving Japanese Society of Pediatric Surgeons-accredited hospitals and their associated hospitals (AHs) was conducted with an anonymous questionnaire. Results: Responses to the survey were obtained from 92 (63.9%) of 144 AHs. During the last 5 years, treatments of childhood malignant solid tumors were performed in 62 AHs (67.4%). THP was used in 47 (83.9%) of 56 AHs that treated neuroblastoma and 43 (87.8%) of 49 AHs that treated liver tumors (hepatoblastoma and hepatocellular carcinoma). THP was also used in 15 (36.6%) of 41 AHs that treated rhabdomyosarcoma, 10 (22.7%) of 44 AHs that treated nephroblastoma, and 7 (14.9%) of 47 AHs that treated malignant germ cell tumors. Intention to use THP in future cases of neuroblastoma and liver tumors was expressed in 62 AHs (67.4%) and 59 AHs (64.1%), respectively. Only 11 AHs (12.0%) expressed no intention to use THP in treatment of future cases of malignant solid tumors. There was a case in an AH where medical fees payment was rejected by the social insurance medical fee payment fund, and another AH where payment requests for THP was ignored. Conclusions: THP is widely used as an off-label treatment for malignant solid tumors in children. Administrative personnel and offices involved in pharmaceutical affairs should look into and resolve issues regarding the off-label treatment use of THP shown in the present study.

Journal

• Journal of the Japanese Society of Pediatric Surgeons

  Journal of the Japanese Society of Pediatric Surgeons 48 (4), 727-730, 2012

  The Japanese Society of Pediatric Surgeons

Keywords

• pirarubicin (THP)
• off-label use

Details

• CRID: 1390001204831454592
• NII Article ID: 110009470926
• NII Article ID: 10031084913
• NII Book ID: AN00192281
• DOI: 10.11164/jjsps.48.4_727
• ISSN: 21874247
• ISSN: 0288609X
• NDL BIB ID: 023864643
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I023864643
• Web Site: https://search.jamas.or.jp/link/ui/2012316209
• Text Lang: ja
• Data Source:
  • JaLC
  • NDL
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed